Abstracts tagged "Etanercept and juvenile idiopathic arthritis (JIA)"

Abstract Number: 2273 • 2017 ACR/ARHP Annual Meeting
An Open-Label Extension Study to Assess the Long-Term Safety of Etanercept in Pediatric Patients with Extended Oligo, Enthesitis Related, and Psoriatic Juvenile Idiopathic Arthritis: 6-Year Data from the Clipper Studies
Ivan Foeldvari¹, Tamas Constantin¹, Jelena Vojinovic², Gerd Horneff¹, Joke Dehoorne¹, Gordana Susic¹, Katarzyna Kobusinska¹, Violeta Vladislava Panaviene¹, Zbigniew Zuber¹, Valda Stanevicha¹, Vyacheslav Chasnyk¹, Ronald Pedersen³, Jack F Bukowski⁴, Tina Hinnershitz⁵, Bonnie Vlahos⁶, Alberto Martini¹ and Nicolino Ruperto¹, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Jersey, ³Department of Biostatistics, Pfizer, Collegeville, PA, ⁴Clinical Affairs, Pfizer, Collegeville, PA, ⁵Specialty Care MDG, Pfizer, Collegeville, PA, ⁶Clinical Sciences, Pfizer, Collegeville, PA
Background/Purpose: A Phase 3b, open-label (OL), multicenter study (CLIPPER) has shown the safety of etanercept (ETN) in pediatric patients (pts) with extended oligoarticular (eo) juvenile…
Abstract Number: 3010 • 2016 ACR/ARHP Annual Meeting
Improvement of Spinal Inflammation Induced By Etanercept in Enthesitis Related Arthritis JIA-Patients. Data of the Reminder-Study
Gerd Horneff¹, Ivan Foeldvari², Kirsten Minden^3,4, Hans-Iko Huppertz⁵ and Ariane Klein⁶, ¹Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ²Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ³Epidemiology, Charite, DRFZ, Berlin, Germany, ⁴Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁵Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ⁶Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: The data of the REMINDER study, a two-part, 48-week, randomized, placebo-controlled, double-blind withdrawal study on efficacy of etanercept (ETA) compared to placebo (PLC) in…
Abstract Number: 293 • 2013 ACR/ARHP Annual Meeting
The Efficacy Of Etanercept In Patients With Juvenile Idiopathic Arthritis With Inadequate Response To Infliximab As a First TNF Inhibitor
Ekaterina Alekseeva^1,2, Tatyana Bzarova³, Anna Fetisova³, Tatyana Sleptsova³, Saniya Valieva³, Kseniya Isayeva³, Rina Denisova³, Elena Mitenko³, Evgeniya Chistyakova³ and Nikolay Taybulatov⁴, ¹PRINTO, Genoa, Italy, ²I.M.Sechenov First Moscow State Medical University, Moscow, Russia, ³Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ⁴Orthopedic, Scientific Center of Children's Health of RAMS, Moscow, Russia
Background/Purpose: Lack of efficacy of Methotrexate, primary and secondary resistance to biologics and their intolerance lead to juvenile idiopathic arthritis (JIA) of progression. Therefore, the problem of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].